Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States

Epilepsia

Volumn 51, Issue 5, 2010, Pages 838-844

  Ivanova, Jasmina I ^a   Birnbaum, Howard G ^a   Kidolezi, Yohanne ^a   Qiu, Ying ^b   Mallett, David ^c   Caleo, Sue ^d  

^a ANALYSIS GROUP   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Ingenix Employer Solutions   (United States)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Costs; Economic burden; Indirect costs; Partial epilepsy; Partial onset seizures; Work loss

Indexed keywords

ANTICONVULSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CONVULSION; EPILEPSY; FEMALE; FOCAL EPILEPSY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

ABSENTEEISM; ADULT; ANTICONVULSANTS; COST OF ILLNESS; DRUG COSTS; EPILEPSIES, PARTIAL; EPILEPSY; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; UNITED STATES;

EID: 77951549485     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02422.x     Document Type: Article

References (17)

1. Begley CE, Annegers JF, Lairson DL, Reynolds TF, Hauser WA. (1994) Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35:1230-1243. (Pubitemid 24379437)
2. Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, Dubinsky S, Newmark ME, Leibson C, So EL, Rocca WA. (2000) The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41:342-351. (Pubitemid 30134292)
3. Begley CE, Lairson DR, Reynolds TF, Coan S. (2001) Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res 47:205-215.
4. Birnbaum HG, Ivanova JI, Kidolezi Y, Caleo S. (2008a) Epilepsy cost of illness in the U.S. privately insured. Value Health 11:A602.
5. Birnbaum HG, Ivanova JI, Kidolezi Y, Caleo S. (2008b) The indirect cost burden of epilepsy in the United States. Value Health 11:A604.
6. Casino GD. (1990) Intractable partial epilepsy: evaluation and treatment. Mayo Clinic Proc 65:1578-1586.
7. Charlson ME, Pompei P, Ales KL, Ales KL, MacKenzie CR. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. (Pubitemid 17055592)
8. French JA. (2007) Refractory epilepsy: clinical overview. Epilepsia 48(suppl 1):3-7.
9. Halpern M, Rentz A, Murray M. (2000) Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 19:87-99. (Pubitemid 30111737)
10. Health Affairs (2002) Press release: number of Americans with job-based health benefits grew through Early 2001; despite higher benefit costs. January 8, 2002. Available at: http://www.healthaffairs.org/press/janfeb0202.htm. [accessed June 17, 2002].
11. Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D. (2009) The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 27:681-691.
12. Kwan P, Brodie MJ. (2000) Early identification of refractory epilepsy. N Engl J Med 342:314-319.
13. Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG. (2008) Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin 24:1549-1559. (Pubitemid 351741588)
14. Murray MI, Halpern MT, Lepik IE. (1996) Cost of refractory epilepsy in adults in the USA. Epilepsy Res 23:139-148.
15. Romano PS, Roos LL, Jollis J. (1993) Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 46:1075-1079.
16. Strzelczyk A, Reese JP, Dodel R, Hamer HM. (2008) Cost of epilepsy: a systematic review. Pharmacoeconomics 26:463-476.
17. World Health Organization (February 2001). Epilepsy: aetiogy, epidemiology and prognosis. 〈http://www.who.int/mediacentre/factsheets/ fs165/en/〉 Retrieved on 4/29/2008.